The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
 
Yasutoshi Kuboki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tetsuji Terazawa
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Jun Watanabe
Speakers' Bureau - Covidien; Johnson & Johnson/Janssen
 
Hitoshi Ojima
No Relationships to Disclose
 
Yudai Shinohara
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroki Hara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; dainippon sumitomo; Lilly; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ohta
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Teijin Pharma
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD K.K; Nippon Kayaku; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; MSD K.K; Takeda
Research Funding - Chugai Pharma; Lilly Japan; Nihonkayaku; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Soichiro Ishihara
Honoraria - Chugai Pharma; EA Pharma; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Mitsubishi Tanabe Pharma; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); EA Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mitsubishi Tanabe Pharma (Inst); Miyarisan Pharmaceutical (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Takako Eguchi Nakajima
Honoraria - Amgen; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo; Lilly Japan; MERCK SERONO; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; ICON Clinical Research; Japan Clinical Research Operations; Lilly Japan; Mediscience Planning; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; PAREXEL; Sanofi; Solasia Pharma; Taiho Pharmaceutical; Takeda
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst)
 
Kuniaki Shirao
Consulting or Advisory Role - Taiho Pharmaceutical; Yakult Honsha
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)